SNY : Summary for Sanofi American Depositary Shar - Yahoo Finance

U.S. Markets open in 7 hrs 3 mins

Sanofi (SNY)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
46.91+0.49 (+1.06%)
At close: 4:01PM EDT
People also watch
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Previous Close46.42
Bid0.00 x
Ask0.00 x
Day's Range46.42 - 46.92
52 Week Range36.81 - 46.92
Avg. Volume1,493,435
Market Cap117.15B
PE Ratio (TTM)24.27
Earnings DateN/A
Dividend & Yield1.58 (3.46%)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Reuters50 minutes ago

    Genzyme, CHC lift Sanofi's first-quarter figures, upbeat on Dupixent

    French drugmaker Sanofi reported higher-than-expected first-quarter profits on Friday, buoyed by its specialty care division Genzyme, by vaccines, and by consumer products acquired from Germany's Boehringer ...

  • PR Newswire1 hour ago

    Regeneron and Sanofi Announce Kevzara® (sarilumab) Biologics License Application Resubmission Accepted for Review by U.S. FDA

    TARRYTOWN, N.Y. and PARIS, April 28, 2017 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi today announced that the U.S. Food and Drug Administration has accepted the resubmission of the Biologics License Application for Kevzara (sarilumab) as a Class I response with a two month review timeline. Kevzara is an investigational human monoclonal antibody directed against the IL-6 receptor being evaluated for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to one or more disease modifying antirheumatic drugs (DMARDs), such as methotrexate. The companies recently received a positive opinion for Kevzara from the European Medicine Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP), and the European Commission (EC) is expected to make a final decision on the Marketing Authorization Application (MAA) for Kevzara in the European Union in the coming months.

  • Amgen's Q1 Results Highlight the Need for an Acquisition
    Motley Fool17 hours ago

    Amgen's Q1 Results Highlight the Need for an Acquisition

    Is it time for Amgen to spend some of its cash stockpile? The big biotech's Q1 results say "yes."